Ulinastatin combined with thymosin α1 for treatment of severe sepsis: a histopathological observation in rats.
- Author:
Jianying GUO
1
;
Qun DENG
;
Xusheng GUO
;
Shuangqing LIU
;
Yuhong ZHANG
;
Zhongjie HE
;
Hongyuan LIN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Apoptosis; Drug Therapy, Combination; Glycoproteins; therapeutic use; Male; Rats; Rats, Wistar; Sepsis; drug therapy; pathology; Spleen; cytology; pathology; Thymosin; analogs & derivatives; therapeutic use
- From: Journal of Southern Medical University 2012;32(6):830-834
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the therapeutic effect of ulinastatin combined with thymosin α1 in the treatment of severe sepsis in rats.
METHODSNormal Wistar rats were subject to cecal ligation and puncture (CLP) to establish models of severe sepsis. The rats were then randomized into 4 groups for treatment with saline (control), ulinastatin, thymosin α1, or the combination of the latter two injected through the caudal vein or subcutaneously at 6, 24, 48 and 72 h after modeling. The mortality rate was recorded daily and the rats were executed at 24, 48, 72 and 96 h after CLP to harvest the heart, liver, spleen, lung, kidney and small intestines for pathological examination. The spleen of the rats were taken for detection of apoptosis of the spleen cells.
RESULTSThe mortality rate of the septic rats in the combined treatment group was decreased significantly (P=0.0325). The control group showed the most severe organ damage, which was moderate in single drug treatment group and the mildest in combined treatment group. Obvious spleen cell apoptosis was found in the control group, and was significantly ameliorated in the combined treatment group[(47.4∓10.9)% vs (39.3∓11.4)%, P=0.0000].
CONCLUSIONCombined treatment with ulinastatin and thymosin α1 can significantly improve the prognosis and ameliorate organ damage and spleen cell apoptosis in rats with sever sepsis.
